株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の肺炎球菌ワクチン市場:機会分析および業界予測 ワクチンのタイプ、製品のタイプ、セクター別、流通チャネル別

Pneumonia Vaccine Market by Vaccine Type, by Product Type and By Sector, by Distribution Channel : Opportunity Analysis and Industry Forecast, 2018-2025

発行 Allied Market Research 商品コード 881855
出版日 ページ情報 英文 171 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.74円で換算しております。
Back to Top
世界の肺炎球菌ワクチン市場:機会分析および業界予測 ワクチンのタイプ、製品のタイプ、セクター別、流通チャネル別 Pneumonia Vaccine Market by Vaccine Type, by Product Type and By Sector, by Distribution Channel : Opportunity Analysis and Industry Forecast, 2018-2025
出版日: 2019年05月31日 ページ情報: 英文 171 Pages
概要

世界の肺炎球菌ワクチン市場は2017年に70億8,300万米ドルとなりました。同市場は2018年から2025年の間に5%のCAGRで成長する見通しで、2025年には102億1510万米ドルに達すると予測されています。

当レポートでは世界の肺炎球菌ワクチン市場について調査しており、市場規模および予測、市場動向、ワクチンのタイプ・製品タイプ・セクター・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • レポートの説明
  • ステークホルダーの主な利点
  • 主な市場セグメント
  • 調査方法
    • 二次研究
    • 一次研究
    • 解析ツールおよびモデル

第2章 エグゼクティブサマリー

  • 研究の主な調査結果
  • CXOの視点

第3章 市場の概要

  • 市場の定義および範囲
  • 主な調査結果
    • 主要な投資銘柄
    • 主要な勝利戦略
    • 主要な戦略
  • ポーターのファイブフォース分析
    • サプライヤーの交渉力
    • 新規参入の脅威
    • 代替品の脅威
    • 業界内の競争
    • バイヤー間の交渉力
  • 市場シェア分析
  • 市場の動向
    • 成長要因
    • 阻害要因
    • 市場機会

第4章 肺炎球菌ワクチン市場:ワクチン種類別

  • 概要
    • 市場規模および予測
  • 結合型ワクチン(PCV)
    • 主な市場動向、成長要因および機会
    • 市場規模および予測
  • 多糖体ワクチン(PPSV / PPV)
    • 主な市場動向、成長要因および機会
    • 市場規模および予測

第5章 肺炎球菌ワクチン市場:製品タイプ別

  • 概要
    • 市場規模および予測
  • Prevnar
    • 主な市場動向、成長要因および機会
    • 市場規模および予測
  • Synflorix
    • 主な市場動向、成長要因および機会
    • 市場規模および予測
  • Pneumovax23
    • 主な市場動向、成長要因および機会
    • 市場規模および予測
  • パイプライン製品

第6章 肺炎球菌ワクチン市場:セクター別

  • 概要
    • 市場規模および予測
  • 公的機関
    • 市場規模および予測
  • 民間部門
    • 市場規模および予測

第7章 肺炎球菌ワクチン市場:流通チャネル別

  • 概要
    • 市場規模および予測
  • 流通パートナー企業
    • 主な市場動向、成長要因および機会
    • 市場規模および予測
  • 非政府組織(NGO)
    • 主な市場動向、成長要因および機会
    • 市場規模および予測
  • 政府機関
    • 主な市場動向、成長要因および機会
    • 市場規模および予測

第8章 世界の肺炎球菌ワクチン:地域別

  • 概要
    • 市場規模および予測
  • 北米
    • 主な市場動向
    • 主な成長要因および機会
    • タイプ別
    • 製品タイプ別
    • 流通チャネル別
    • セクター別
    • 国別
  • 欧州
    • 主な市場動向
    • 主な成長要因および機会
    • タイプ別
    • 製品タイプ別
    • 流通チャネル別
    • セクター別
    • 国別
  • アジア太平洋地域
    • 主な市場動向
    • 主な成長要因および機会
    • タイプ別
    • 製品タイプ別
    • 流通チャネル別
    • セクター別
    • 国別
  • ラテンアメリカ・中東・アフリカ
    • 主な市場動向
    • 主な成長要因および機会
    • タイプ別
    • 製品タイプ別
    • 流通チャネル別
    • セクター別
    • 国別

第9章 企業プロファイル

  • GLAXOSMITHKLINE PLC.
  • LG CHEM LTD.
  • MERCK & CO., INC.
  • PANACEA BIOTEC LIMITED
  • PFIZER INC.
  • PNUVAX INCORPORATED
  • SERUM INSTITUTE OF INDIA PVT. LTD.
  • SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. (BEIJING MINHAI BIOTECHNOLOGY CORPORATION LIMITED)
  • SK BIOSCIENCE
  • WALVAX BIOTECHNOLOGY CO., LTD.
図表

LIST OF TABLES

  • TABLE 01. PNEUMONIA VACCINES MARKET, BY VACCINE TYPE, 2017-2025 ($MILLION)
  • TABLE 02. PNEUMONIA VACCINES MARKET FOR PNEUMOCOCCAL CONJUGATE VACCINES, BY REGION, 2017-2025 ($MILLION)
  • TABLE 03. PNEUMONIA VACCINES MARKET FOR PNEUMOCOCCAL POLYSACCHARIDE VACCINES, BY REGION, 2017-2025 ($MILLION)
  • TABLE 04. PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 05. PNEUMONIA VACCINE MARKET FOR PREVNAR 13, BY REGION, 2017-2025 ($MILLION)
  • TABLE 06. PNEUMONIA VACCINE MARKET FOR PREVNAR 13, BY TARGET POPULATION, 2017-2025 ($MILLION)
  • TABLE 07. PNEUMONIA VACCINE MARKET FOR SYNFLORIX, BY REGION, 2017-2025 ($MILLION)
  • TABLE 08. PNEUMONIA VACCINE MARKET FOR SYNFLORIX, BY TARGET POPULATION, 2017-2025 ($MILLION)
  • TABLE 09. PNEUMONIA VACCINE MARKET FOR PNEUMOVAX23, BY REGION, 2017-2025 ($MILLION)
  • TABLE 10. PNEUMONIA VACCINE MARKET FOR PNEUMOVAX, BY TARGET POPULATION, 2017-2025 ($MILLION)
  • TABLE 11. PNEUMONIA VACCINE PRODUCT PIPELINE
  • TABLE 12. PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 13. PNEUMONIA VACCINE MARKET BY PUBLIC SECTOR, 2017-2025 ($MILLION)
  • TABLE 14. PNEUMONIA VACCINE MARKET, BY PRIVATE SECTOR, 2017-2025 ($MILLION)
  • TABLE 15. PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 16. PNEUMONIA VACCINE MARKET FOR DISTRIBUTION PARTNER COMPANIES, BY REGION, 2017-2025 ($MILLION)
  • TABLE 17. PNEUMONIA VACCINE MARKET FOR NON-GOVERNMENTAL ORGANIZATIONS, BY REGION, 2017-2025 ($MILLION)
  • TABLE 18. PNEUMONIA VACCINE MARKET FOR GOVERNMENT AUTHORITIES, BY REGION, 2017-2025 ($MILLION)
  • TABLE 19. PNEUMONIA VACCINE MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 20. NORTH AMERICA PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 21. NORTH AMERICA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 22. NORTH AMERICAPNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 23. NORTH AMERICAPNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 24. NORTH AMERICA PNEUMONIA VACCINE MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 25. THE U.S. PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 26. THE U.S. PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 27. THE U.S. PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 28. THE U.S. PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 29. CANADA PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 30. CANADA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 31. CANADA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 32. CANADA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 33. MEXICO PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 34. MEXICO PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 35. MEXICO PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 36. MEXICO PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 37. EUROPE PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 38. EUROPE PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 39. EUROPE PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 40. EUROPE PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 41. EUROPE PNEUMONIA VACCINE MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 42. GERMANY PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 43. GERMANY PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 44. GERMANY PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 45. GERMANY PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 46. FRANCE PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 47. FRANCE PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 48. FRANCE PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 49. FRANCE PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 50. UK PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 51. UK PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 52. UK PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 53. UK PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 54. SPAIN PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 55. SPAIN PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 56. SPAIN PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 57. SPAIN PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 58. ITALY PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 59. ITALY PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 60. ITALY PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 61. ITALY PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 62. REST OF EUROPE PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 63. REST OF EUROPE PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 64. REST OF EUROPE PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 65. REST OF EUROPE PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 66. ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 67. ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 68. ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 69. ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 70. ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 71. JAPAN PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 72. JAPAN PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 73. JAPAN PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 74. JAPAN PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 75. CHINA PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 76. CHINA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 77. CHINA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 78. CHINA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 79. INDIA PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 80. INDIA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 81. INDIA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 82. INDIA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 83. REST OF ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 84. REST OF ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 85. REST OF ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 86. REST OF ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 87. LAMEA PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 88. LAMEA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 89. LAMEA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 90. LAMEA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 91. LAMEA PNEUMONIA VACCINE MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 92. BRAZIL PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 93. BRAZIL PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 94. BRAZIL PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 95. BRAZIL PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 96. SOUTH AFRICA PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 97. SOUTH AFRICA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 98. SOUTH AFRICA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 99. SOUTH AFRICA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 100. SAUDI ARABIA PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 101. SAUDI ARABIA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 102. SAUDI ARABIA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 103. SAUDI ARABIA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 104. REST OF LAMEA PNEUMONIA VACCINE MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 105. REST OF LAMEA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017-2025 ($MILLION)
  • TABLE 106. REST OF LAMEA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
  • TABLE 107. REST OF LAMEA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017-2025 ($MILLION)
  • TABLE 108. GSK: COMPANY SNAPSHOT
  • TABLE 109. GSK: OPERATING SEGMENTS
  • TABLE 110. GSK: PRODUCT PORTFOLIO
  • TABLE 111. LG CHEM: COMPANY SNAPSHOT
  • TABLE 112. LG CHEM: OPERATING SEGMENTS
  • TABLE 113. KINDER MORGAN: PRODUCT PORTFOLIO
  • TABLE 114. MERCK: COMPANY SNAPSHOT
  • TABLE 115. MERCK: OPERATING SEGMENTS
  • TABLE 116. MERCK: PRODUCT PORTFOLIO
  • TABLE 117. PANACEA BIOTEC: COMPANY SNAPSHOT
  • TABLE 118. PANACEA BIOTEC: OPERATING SEGMENTS
  • TABLE 119. PANACEA BIOTEC: PRODUCT PORTFOLIO
  • TABLE 120. PFIZER: COMPANY SNAPSHOT
  • TABLE 121. PFIZER: OPERATING SEGMENTS
  • TABLE 122. PFIZER: PRODUCT PORTFOLIO
  • TABLE 123. PNUVAX: COMPANY SNAPSHOT
  • TABLE 124. PNUVAX: PRODUCT PORTFOLIO
  • TABLE 125. SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 126. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 127. SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.: COMPANY SNAPSHOT
  • TABLE 128. SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 129. SK BIOSCIENCE: COMPANY SNAPSHOT
  • TABLE 130. SK BIOSCIENCE: PRODUCT PORTFOLIO
  • TABLE 131. WALVAX: COMPANY SNAPSHOT
  • TABLE 132. WALVAX: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. PNEUMONIA VACCINES MARKET SEGMENTATION
  • FIGURE 02. TOP INVESTMENT POCKETS
  • FIGURE 03. BARGAINING POWER OF SUPPLIERS
  • FIGURE 04. THREAT OF NEW ENTRANTS
  • FIGURE 05. THREAT OF SUBSTITUTES
  • FIGURE 06. COMPETITIVE RIVALRY
  • FIGURE 07. BARGAINING POWER AMONG BUYERS
  • FIGURE 08. MARKET SHARE ANALYSIS, 2018
  • FIGURE 09. IMPACT ANALYSIS
  • FIGURE 10. GSK: REVENUE, 2016-2018 ($MILLION)
  • FIGURE 11. GSK: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 12. GSK: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 13. LG CHEM: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 14. LG CHEM: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 15. LG CHEM: REVENUE SHARE BY REGION, 2017 (%)
  • FIGURE 16. MERCK: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 17. MERCK: NET SALES BY SEGMENT, 2018 (%)
  • FIGURE 18. MERCK: NET SALES BY REGION, 2018 (%)
  • FIGURE 19. PANACEA BIOTEC: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 20. PANACEA BIOTEC: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 21. PANACEA BIOTEC: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 22. PFIZER: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 23. PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 24. PFIZER: REVENUE SHARE BY REGION, 2018 (%)
目次
Product Code: LI_182730

Title:
Pneumonia Vaccine Market by Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine), by Product Type (Prevnar 13, Synflorix, and Pneumovax 23) and By Sector (Public and Private), by Distribution Channel (Distribution Partner Companies, Non-governmental Organizations and Government Authorities): Opportunity Analysis and Industry Forecast, 2018-2025.

The global pneumonia vaccines market was valued at $7,083 million in 2017 and is expected to reach $10,215 million by 2025, growing at a CAGR of 5% from 2018 to 2025.

Pneumonia is a lung infection that occurs in one or both the lungs caused by bacteria, viruses, or fungi; however, bacterial pneumonia is the most common form occurring in adults.

Pneumonia results in inflammation in the air sacs (known as alveoli) of the lungs, which results in filling the alveoli with fluid (pus cells), thus causing breathing problems. Pneumococcal disease is common in young children, but older adults are at greatest risk of serious pneumococcal infections and even death.

Thus, Center for Disease Control and Prevention (CDC) recommends administration of two pneumococcal vaccines, PCV13 and PPSV23. The key factors that drive the growth of the global pneumonia vaccine market include increase in prevalence of pneumonia across the globe, rise in government focus on immunization programs for pneumonia, and introduction of novel pneumococcal vaccines such as PCV10. However, longer timelines required for pneumonia vaccine production and high cost associated with the development of such vaccines restrain the market growth. Moreover, development of protein-based combination pneumococcal vaccines is expected to provide lucrative opportunities for the expansion of this market.

The global pneumonia vaccine market is segmented based on type, product, distribution channel, sector, and region. Based on type, the market is bifurcated into pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPV). Products covered in the study include Synflorix, Prevnar 13, PPSV- 23, PCV 13-PIPELINE, V114-MERCK, PCV-20-PFIZER, and PCV-10-SII. Based on distribution channel, the market is categorized into distribution partner companies, non-governmental organizations (NGO), and government authorities. Based on sector, the market is bifurcated into public and private. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Analysis by type helps understand the various types of pneumonia vaccines used by healthcare providers.
  • Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
  • Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Vaccine Type

  • Pneumococcal Conjugate Vaccine
  • Pneumococcal Polysaccharide Vaccine

By Product Type

  • Prevnar 13
  • Synflorix
  • Pneumovax 23

By Sector

  • Public
  • Private

By distribution channel

  • Distribution Partner Companies
  • Non-governmental Organizations (NGO)
  • Government Authorities

By Country

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT (VACCINE PROVIDERS):

  • Glaxosmithkline plc.
  • LG Chem Ltd.
  • Merck & Co., Inc.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Pnuvax Incorporated
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited)
  • SK Bioscience
  • Walvax Biotechnology Co., Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits for stakeholders
  • 1.3. Key market segments
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. Key findings of the study
  • 2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies, 2016-2018
    • 3.2.3. Top strategies:
  • 3.3. Porters five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Threat of new entrants
    • 3.3.3. Threat of substitutes
    • 3.3.4. Competitive rivalry
    • 3.3.5. Bargaining power among buyers
  • 3.4. Market share analysis, 2018
  • 3.5. Market dynamics
    • 3.5.1. Drivers
      • 3.5.1.1. Surge in prevalence of pneumonia across the globe
      • 3.5.1.2. Rise in government focus on immunization programs for pneumonia
      • 3.5.1.3. Increase in focus for novel pneumococcal vaccines
    • 3.5.2. Restraints
      • 3.5.2.1. Longer timelines required for pneumonia vaccine production
      • 3.5.2.2. High cost associated with development of such vaccines
    • 3.5.3. Opportunity
      • 3.5.3.1. Development of protein-based combination pneumococcal vaccines

CHAPTER 4: PNEUMONIA VACCINES MARKET, BY VACCINE TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Pneumococcal conjugate vaccine (PCV)
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast
  • 4.3. Pneumococcal polysaccharide vaccine (PPSV/PPV)
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast

CHAPTER 5: PNEUMONIA VACCINES MARKET, BY PRODUCT TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Prevnar 13
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast
  • 5.3. Synflorix
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast
  • 5.4. Pneumovax23
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast
  • 5.5. Pipeline Products

CHAPTER 6: PNEUMONIA VACCINES MARKET, BY SECTOR

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Public sector
    • 6.2.1. Market size and forecast
  • 6.3. Private sector
    • 6.3.1. Market size and forecast

CHAPTER 7: PNEUMONIA VACCINES MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Distribution partner companies
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast
  • 7.3. Non-governmental Organizations (NGO)
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast
  • 7.4. Government Authorities
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast

CHAPTER 8: GLOBAL PNEUMONIA MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast
  • 8.2. North America
    • 8.2.1. Key market trends
    • 8.2.2. Key growth factors and opportunities
    • 8.2.3. Market size and forecast, by type
    • 8.2.4. Market size and forecast, by product type
    • 8.2.5. Market size and forecast, by distribution channel
    • 8.2.6. Market size and forecast, by sector
    • 8.2.7. Market size and forecast, by country
      • 8.2.7.1. The U.S. Pneumonia Vaccine Market
      • 8.2.7.1.1. Market Size and forecast, by type
      • 8.2.7.1.2. Market Size and forecast, by product type
      • 8.2.7.1.3. Market Size and forecast, by distribution channel
      • 8.2.7.1.4. Market Size and forecast, by sector
      • 8.2.7.2. Canada Pneumonia Vaccine Market
      • 8.2.7.2.1. Market Size and forecast, by type
      • 8.2.7.2.2. Market Size and forecast, by product type
      • 8.2.7.2.3. Market Size and forecast, by distribution channel
      • 8.2.7.2.4. Market Size and forecast, by sector
      • 8.2.7.3. Mexico Pneumonia Vaccine Market
      • 8.2.7.3.1. Market Size and forecast, by type
      • 8.2.7.3.2. Market Size and forecast, by product type
      • 8.2.7.3.3. Market Size and forecast, by distribution channel
      • 8.2.7.3.4. Market Size and forecast, by sector
  • 8.3. Europe
    • 8.3.1. Key market trends
    • 8.3.2. Key growth factors and opportunities
    • 8.3.3. Market size and forecast, by type
    • 8.3.4. Market size and forecast, by product type
    • 8.3.5. Market size and forecast, by distribution channel
    • 8.3.6. Market size and forecast, by sector
    • 8.3.7. Market size and forecast, by country
      • 8.3.7.1. Germany Pneumonia Vaccine Market
      • 8.3.7.1.1. Market Size and forecast, by type
      • 8.3.7.1.2. Market Size and forecast, by product type
      • 8.3.7.1.3. Market Size and forecast, by distribution channel
      • 8.3.7.1.4. Market Size and forecast, by sector
      • 8.3.7.2. France Pneumonia Vaccine Market
      • 8.3.7.2.1. Market Size and forecast, by type
      • 8.3.7.2.2. Market Size and forecast, by product type
      • 8.3.7.2.3. Market Size and forecast, by distribution channel
      • 8.3.7.2.4. Market Size and forecast, by sector
      • 8.3.7.3. UK Pneumonia Vaccine Market
      • 8.3.7.3.1. Market Size and forecast, by type
      • 8.3.7.3.2. Market Size and forecast, by product type
      • 8.3.7.3.3. Market Size and forecast, by distribution channel
      • 8.3.7.3.4. Market Size and forecast, by sector
      • 8.3.7.4. Spain Pneumonia Vaccine Market
      • 8.3.7.4.1. Market Size and forecast, by type
      • 8.3.7.4.2. Market Size and forecast, by product type
      • 8.3.7.4.3. Market Size and forecast, by distribution channel
      • 8.3.7.4.4. Market Size and forecast, by sector
      • 8.3.7.5. Italy Pneumonia Vaccine Market
      • 8.3.7.5.1. Market Size and forecast, by type
      • 8.3.7.5.2. Market Size and forecast, by product type
      • 8.3.7.5.3. Market Size and forecast, by distribution channel
      • 8.3.7.5.4. Market Size and forecast, by sector
      • 8.3.7.6. Rest of Europe Pneumonia Vaccine Market
      • 8.3.7.6.1. Market Size and forecast, by type
      • 8.3.7.6.2. Market Size and forecast, by product type
      • 8.3.7.6.3. Market Size and forecast, by distribution channel
      • 8.3.7.6.4. Market Size and forecast, by sector
  • 8.4. Asia-Pacific
    • 8.4.1. Key market trends
    • 8.4.2. Key growth factors and opportunities
    • 8.4.3. Market size and forecast, by type
    • 8.4.4. Market size and forecast, by product type
    • 8.4.5. Market size and forecast, by distribution channel
    • 8.4.6. Market size and forecast, by sector
    • 8.4.7. Market size and forecast, by country
      • 8.4.7.1. Japan Pneumonia Vaccine Market
      • 8.4.7.1.1. Market Size and forecast, by type
      • 8.4.7.1.2. Market Size and forecast, by product type
      • 8.4.7.1.3. Market Size and forecast, by distribution channel
      • 8.4.7.1.4. Market Size and forecast, by sector
      • 8.4.7.2. China Pneumonia Vaccine Market
      • 8.4.7.2.1. Market Size and forecast, by type
      • 8.4.7.2.2. Market Size and forecast, by product type
      • 8.4.7.2.3. Market Size and forecast, by distribution channel
      • 8.4.7.2.4. Market Size and forecast, by sector
      • 8.4.7.3. India Pneumonia Vaccine Market
      • 8.4.7.3.1. Market Size and forecast, by type
      • 8.4.7.3.2. Market Size and forecast, by product type
      • 8.4.7.3.3. Market Size and forecast, by distribution channel
      • 8.4.7.3.4. Market Size and forecast, by sector
      • 8.4.7.4. Rest of Asia-Pacific Pneumonia Vaccine Market
      • 8.4.7.4.1. Market Size and forecast, by type
      • 8.4.7.4.2. Market Size and forecast, by product type
      • 8.4.7.4.3. Market Size and forecast, by distribution channel
      • 8.4.7.4.4. Market Size and forecast, by sector
  • 8.5. LAMEA
    • 8.5.1. Key market trends
    • 8.5.2. Key growth factors and opportunities
    • 8.5.3. Market size and forecast, by type
    • 8.5.4. Market size and forecast, by product type
    • 8.5.5. Market size and forecast, by distribution channel
    • 8.5.6. Market size and forecast, by sector
    • 8.5.7. Market size and forecast, by country
      • 8.5.7.1. Brazil Pneumonia Vaccine Market
      • 8.5.7.1.1. Market Size and forecast, by type
      • 8.5.7.1.2. Market Size and forecast, by product type
      • 8.5.7.1.3. Market Size and forecast, by distribution channel
      • 8.5.7.1.4. Market Size and forecast, by sector
      • 8.5.7.2. South Africa Pneumonia Vaccine Market
      • 8.5.7.2.1. Market Size and forecast, by type
      • 8.5.7.2.2. Market Size and forecast, by product type
      • 8.5.7.2.3. Market Size and forecast, by distribution channel
      • 8.5.7.2.4. Market Size and forecast, by sector
      • 8.5.7.3. Saudi Arabia Pneumonia Vaccine Market
      • 8.5.7.3.1. Market Size and forecast, by type
      • 8.5.7.3.2. Market Size and forecast, by product type
      • 8.5.7.3.3. Market Size and forecast, by distribution channel
      • 8.5.7.3.4. Market Size and forecast, by sector
      • 8.5.7.4. Rest of LAMEA Pneumonia Vaccine Market
      • 8.5.7.4.1. Market Size and forecast, by type
      • 8.5.7.4.2. Market Size and forecast, by product type
      • 8.5.7.4.3. Market Size and forecast, by distribution channel
      • 8.5.7.4.4. Market Size and forecast, by sector

CHAPTER 9: COMPANY PROFILES

  • 9.1. GLAXOSMITHKLINE PLC.
    • 9.1.1. Company overview
    • 9.1.2. Company snapshot
    • 9.1.3. Operating business segments
    • 9.1.4. Product Portfolio
    • 9.1.5. Business performance
  • 9.2. LG CHEM LTD.
    • 9.2.1. Company overview
    • 9.2.2. Company snapshot
    • 9.2.3. Operating business segments
    • 9.2.4. Product portfolio
    • 9.2.5. Business performance
  • 9.3. MERCK & CO., INC.
    • 9.3.1. Company overview
    • 9.3.2. Company snapshot
    • 9.3.3. Operating business segments
    • 9.3.4. Product Portfolio
    • 9.3.5. Business performance
  • 9.4. PANACEA BIOTEC LIMITED
    • 9.4.1. Company overview
    • 9.4.2. Company snapshot
    • 9.4.3. Operating business segments
    • 9.4.4. Product portfolio
    • 9.4.5. Business performance
  • 9.5. PFIZER INC.
    • 9.5.1. Company overview
    • 9.5.2. Company snapshot
    • 9.5.3. Operating business segments
    • 9.5.4. Product portfolio
    • 9.5.5. Business performance
  • 9.6. PNUVAX INCORPORATED
    • 9.6.1. Company overview
    • 9.6.2. Company snapshot
    • 9.6.3. Product portfolio
  • 9.7. SERUM INSTITUTE OF INDIA PVT. LTD.
    • 9.7.1. Company overview
    • 9.7.2. Company snapshot
    • 9.7.3. Product portfolio
  • 9.8. SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. (BEIJING MINHAI BIOTECHNOLOGY CORPORATION LIMITED)
    • 9.8.1. Company overview
    • 9.8.2. Company snapshot
    • 9.8.3. Product portfolio
  • 9.9. SK BIOSCIENCE
    • 9.9.1. Company overview
    • 9.9.2. Company snapshot
    • 9.9.3. Product portfolio
  • 9.10. WALVAX BIOTECHNOLOGY CO., LTD.
    • 9.10.1. Company overview
    • 9.10.2. Company snapshot
    • 9.10.3. Product Portfolio
Back to Top